Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 135-141, 15 January 2010

Natural history of solitary cerebral cysticercosis on serial magnetic resonance imaging and the effect of albendazole therapy on its evolution

  • A. de Souza

      Affiliations

    • Departments of Neurology, National Institute of Mental Health and NeuroSciences, Bangalore 560 029, India
  • ,
  • A. Nalini

      Affiliations

    • Departments of Neurology, National Institute of Mental Health and NeuroSciences, Bangalore 560 029, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 80 26995139; fax: +91 80 26564830.
  • ,
  • J.M.E. Kovoor

      Affiliations

    • Neuroimaging and Interventional Radiology, National Institute of Mental Health and NeuroSciences, Bangalore 560 029, India
  • ,
  • G. Yeshraj

      Affiliations

    • Departments of Neurology, National Institute of Mental Health and NeuroSciences, Bangalore 560 029, India
  • ,
  • H.S. Siddalingaiah

      Affiliations

    • Departments of Neurology, National Institute of Mental Health and NeuroSciences, Bangalore 560 029, India
  • ,
  • K. Thennarasu

      Affiliations

    • Biostatistics, National Institute of Mental Health and NeuroSciences, Bangalore 560029, India

Received 23 April 2009; received in revised form 19 September 2009; accepted 21 September 2009. published online 30 October 2009.

Abstract 

Aim

To describe the evolution of imaging characteristics of solitary cerebral cysticercal lesions (SCCL) on serial MRI, and to study the effect of treatment with albendazole.

Design

Randomised controlled prospective trial.

Methods and material

123 patients with new-onset seizures and SCCL on contrast MRI were randomised to treatment with albendazole and followed with up to five serial MRIs.

Results

81 patients (M — 41, F — 40) with mean age of 19.6±11.7years and 4 or 5 serial MRI were included in the analysis. Analysis was performed on 356 MRI's. Scolex was seen in 61.9% of patients in postcontrast T1 sequence in the first MRI study, and there was a significant drop in visibility from the next scan onwards. Cyst contents were initially T1-hypointense and T2-hyperintense with inversion on FLAIR in 30.8% and later scans showed T2-hypointensity. Cyst wall characteristics changed significantly from initially T2-hypointensity to later hyperintense rim. Initial scan revealed perilesional oedema in 98.5%, which is resolved by the second scan. Around 17.5% showed subtle perilesional T2-hyperintensity in follow-up scans. Enhancement pattern changed significantly from ring to disc, and later to non-enhancement. Initially, 69.7% lesions were in colloid-vesicular stage. Lesions moved through subsequent stages of cyst degeneration: time needed for this process is described. Imaging characteristics, both on the first and on subsequent scans, did not differ between albendazole and control groups.

Conclusions

Evolution of SCCL follows a predictable sequence corresponding to morphologic stages described earlier, taking over a year to complete. Contrast enhancement decreases as degeneration progresses, but some calcific lesions continue to enhance. Albendazole therapy may hasten resolution of inflammation around the lesion but affects neither the morphology of the cysticercus nor the process of degeneration and subsequent healing.

Keywords: Solitary cerebral cysticercal lesion, Neurocysticercosis, Magnetic resonance imaging, Albendazole, Natural history

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Necessary ethics committee approval was secured for this study from the Institutional Ethics committee board.

PII: S0022-510X(09)00861-2

doi:10.1016/j.jns.2009.09.018

Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 135-141, 15 January 2010